[METAvivor](https://www.metavivor.org)

March 16, 2026 (Required Letter of Intent for Translational Research Award)

Up to $450,000 total over 3 years per award; typically 1–2 awards per cycle.

Supports established investigators pursuing innovative research to advance the understanding, diagnosis, or treatment of metastatic breast cancer.

--- ## Description The METAvivor Translational Research Award funds discovery and early-phase basic, translational, and clinical research that addresses critical barriers in metastatic breast cancer (MBC). The program targets established investigators aiming to make significant progress toward understanding disease mechanisms, improving diagnosis, or developing new treatments for MBC. Research to improve quality of life or address treatment side effects for people living with MBC is also considered. METAvivor emphasizes projects with the potential to transform MBC from a terminal diagnosis into a manageable condition, and encourages multidisciplinary and collaborative approaches. The review process includes both scientific peers and patient advocates, ensuring that funded projects are impactful and relevant to the MBC community. --- ## Due Dates - March 16, 2026: Required Letter of Intent deadline for METAvivor Translational Research Award Invitations to submit full applications are typically sent in June, with full proposals due in August. Awardees are announced in January following the submission cycle. --- ## Funding Amount - Each award provides up to $450,000 total, distributed over three years. - Funds may be used for direct project costs (salary, materials, supplies, and travel), with indirect costs capped at 5% of the total award. - The number of awards per cycle depends on available funding, but typically 1–2 awards are made. --- ## Eligibility - Applicants must hold a clinical doctoral degree or a doctoral degree (e.g., PhD, MD, DO, DVM) from an accredited institution. - Must be established investigators actively engaged in metastatic breast cancer research or treatment. - Applicants must be based at a U.S. academic, nonprofit, or governmental institution; U.S. citizenship is not required, but all research must be conducted in the U.S. - Only one Letter of Intent/application as primary investigator per cycle; may also serve as co-applicant on one other application. - The sponsoring institution must provide necessary facilities and infrastructure, confirmed by a letter of support. - Collaborative, multidisciplinary proposals are encouraged but not required. --- ## Application Process 1. **Letter of Intent (LOI):** Submit by March 16, 2026, via the [METAvivor Grant Portal](https://metavivor.infoready4.com/). - LOI should include a cover page, project significance, impact, rationale, and approach. 2. **Invitation to Apply:** Approximately 20–30% of LOI applicants will be invited in June to submit a full application. 3. **Full Application:** Invited proposals are due in August and must include a detailed research plan, budget, biosketches, letters of support, and other required documents. 4. **Review:** Applications are reviewed by both scientific peers and patient advocates. 5. **Notification:** Awardees are announced in January. Detailed instructions and templates for LOI, budget justification, and progress reports are available on the [grant portal](https://metavivor.infoready4.com/). --- ## Additional Information - Preference is given to research with clear potential to improve clinical outcomes for patients living with established metastatic breast cancer. - Applications focused solely on prevention or diagnosis (not related to established metastases), or without a mechanistic rationale, may be withdrawn. - Awarded projects require regular progress reports at 6 months, 1 year, and 2 years. - Award funds may follow the PI to another U.S. institution with approval. --- ## External Links - [METAvivor Grant Portal](https://metavivor.infoready4.com/) - [2026 Translational Research Award RFP (docx)](https://metavivor.infoready4.com/PlatformServicesV2/Commons/getDocument/METAvivor%202026%20Translational%20Research%20Award%201-14-2026.docx?documentName=56578cea-287c-4433-892a-9de2a4dd9eac.docx&applicationId=7) - [2026 Translational Research Award Budget Justification (docx)](https://metavivor.infoready4.com/PlatformServicesV2/Commons/getDocument/2026%20Translational%20Research%20Award%20Budget%20Justification.docx?documentName=6c0375dc-34ce-4a6f-b323-9a847d61c8ce.docx&applicationId=7) - [METAvivor Grant Application Instructions](https://www.metavivor.org/research/apply-for-a-grant/) - [Contact METAvivor](https://www.metavivor.org/about-us/contact-us/) --- ## Contact Information | Purpose | Contact Details | |------------------------|--------------------------------------------------| | General Inquiries | info@metavivor.org | | Research Program Email | research@metavivor.org | | Grant Portal | [https://metavivor.infoready4.com/](https://metavivor.infoready4.com/) | | Mailing Address | 7780 Elmwood Ave, Suite 130, Middleton, WI 53562, USA | ---

METAvivor Translational Research Award

Sign in to see full grant listing